Top Markets
Coin of the day
PharmAust Limited PharmAust Limited

PharmAust Limited

PAA
Pozycja w akcjach #26700
Operating internationally, including in Switzerland, Australia, Sweden, and the... Operating internationally, including in Switzerland, Australia, Sweden, and the United States, PharmAust Limited specializes in developing targeted cancer treatments for both human and animal applications. The company also cultivates intellectual property in drug discovery, addressing a range of cancers and neurological conditions. Its primary therapeutic candidate is Monepantel (MPL), a small molecule compound currently undergoing Phase II clinical trials for cancer treatment. Beyond its drug development pipeline, PharmAust provides synthetic and medicinal chemistry products and expert services to the global drug discovery and pharmaceutical sectors. The firm also holds a research agreement with the Walter and Eliza Hall Institute, investigating in vitro the effects of MPL on human T-lymphotrophic virus-1 (HTLV-1) infections. Established in 2000, PharmAust Limited is headquartered in Bentley, Australia.
Cena akcji
$0.12164306
Ostatnia synchronizacja: 2024-11-11
Kapitalizacja rynkowa
$38.53M
Zmiana (1 dzień)
-4.14%
Zmiana (1 rok)
0.00%
Kraj
AU
Handel PharmAust Limited (PAA)

Kategoria

Zyski dla PharmAust Limited (PAA)
Zyski w Jun 2024 TTM: $-6.31M
Według najnowszych raportów finansowych PharmAust Limited, obecny zysk firmy wynosi $-6.31M. W roku 2023 firma osiągnęła zysk w wysokości $-4.14M, spadek w porównaniu do zysku z roku 2022, który wynosił $-1.18M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy PharmAust Limited od 2001 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
2026 (TTM) $-6.31M 0.00%
2024 $-6.31M 52.51%
2023 $-4.14M 251.26%
2022 $-1.18M 17.50%
2021 $-1.00M 6.70%
2020 $-939.77K -13.74%
2019 $-1.09M -41.67%
2018 $-1.87M 80.51%
2017 $-1.03M -64.63%
2016 $-2.93M 97.39%
2015 $-1.48M 19.24%
2014 $-1.24M 112.82%
2013 $-584.08K -86.59%
2012 $-4.35M -29.96%
2011 $-6.22M 1,573.65%
2010 $-371.45K 155.62%
2009 $-145.32K -97.37%
2008 $-5.53M -0.89%
2007 $-5.58M 173.13%
2006 $-2.04M -20.13%
2005 $-2.56M 42.56%
2004 $-1.80M 29.13%
2003 $-1.39M -33.40%
2002 $-2.09M 96.03%
2001 $-1.06M 0.00%
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
$5.27B -83,669.91%
US
$1.95B -31,004.03%
NL
$1.61B -25,675.00%
AU
$-3.09B 48,807.15%
US
- -
CH